Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis: A Retrospective Cohort Study
Table 1
Baseline demographics of patients treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).
All patients ()
1 PIPAC ()
2 or >3 PIPAC ()
value
Demographics
Median age (years)
66 (59–73)
62 (52–88)
67 (61–63)
0.185
Age ≥ 70 years
16 (38%)
4 (33%)
12 (40%)
0.687
Gender (male)
8 (19%)
4 (33%)
4 (13%)
0.135
Median BMI (kg/m2)
22.5 (20–25)
19 (19–23)
22.7 (21.3–26)
0.018
BMI < 18.5 kg/m2
2 (5%)
1
1
0.491
Comorbidities
ASA (I-II)
28 (66%)
5 (42%)
23 (77%)
0.029
ECOG (0-1)
36 (86%)
9 (75%)
27 (90%)
0.209
Diabetes
1 (2%)
1
0
0.109
Malnutrition
14 (33%)
7 (58%)
7 (23%)
0.029
29 (69%)
6 (50%)
23 (77%)
0.091
Previous laparotomy
1 (0–4)
1 (0–3)
1 (0–4)
0.040
≥2
15 (36%)
2 (16%)
13 (43%)
0.103
Disease
Origin
0.007
Colorectal
15 (33%)
8 (66%)
6 (20%)
Gastric
3 (7%)
0
3 (10%)
Gynecological
21 (50%)
2 (17%)
19 (63%)
Other
3
1
2
Prior chemotherapy
0.229
No chemo
2
1
1
1 line
9 (21%)
5 (42%)
4 (13%)
2 lines
13 (31%)
2 (17%)
11 (36%)
3 lines
9 (21%)
1
8 (26%)
More than 3
9 (21%)
3 (25%)
6 (20%)
Prior HIPEC
4 (10%)
2 (17%)
2 (7%)
0.318
Diagnosis—1st PIPAC (mo)
16 (1–104)
18 (1–73)
16 (1–104)
0.928
Median (range) for previous laparotomy and diagnosis—1st PIPAC, otherwise median (IQR) or number (%) as appropriate. Statistical significance () is highlighted in italics. BMI: body mass index; ASA: American Association of Anesthesiologists physical status classification system; ECOG: Eastern Cooperative Oncology Group performance status; HIPEC: hyperthermic intraperitoneal chemotherapy.
